TY - BOOK PY - 2007 DA - 2007// TI - Cancer facts and figures 2007 PB - American Cancer Society CY - Atlanta, GA ID - ref1 ER - TY - JOUR AU - Schaake-Koning, C. AU - Bogaert, W. AU - Dalesio, O. AU - Festen, J. AU - Hoogenhot, J. AU - Houtte, P. PY - 1992 DA - 1992// TI - Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer JO - N Engl J Med VL - 326 UR - https://doi.org/10.1056/NEJM199202203260805 DO - 10.1056/NEJM199202203260805 ID - Schaake-Koning1992 ER - TY - JOUR AU - Furuse, K. AU - Fukuoka, M. AU - Kawahara, M. AU - Nishikawa, H. AU - Takada, Y. AU - Kudoh, S. PY - 1999 DA - 1999// TI - Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer JO - J Clin Oncol VL - 17 UR - https://doi.org/10.1200/JCO.1999.17.9.2692 DO - 10.1200/JCO.1999.17.9.2692 ID - Furuse1999 ER - TY - JOUR AU - Curran, W. J. AU - Paulus, R. AU - Langer, C. J. AU - Komaki, R. AU - Lee, J. S. AU - Hauser, S. PY - 2011 DA - 2011// TI - Sequential vs. concurrent chemoradia- tion for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410 JO - J Natl Cancer Inst VL - 103 UR - https://doi.org/10.1093/jnci/djr325 DO - 10.1093/jnci/djr325 ID - Curran2011 ER - TY - JOUR AU - Zatloukal, P. AU - Petruzelka, L. AU - Zemanova, M. AU - Havel, L. AU - Janku, F. AU - Judas, L. PY - 2004 DA - 2004// TI - Concurrent versus sequential chemorad- iotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study JO - Lung Cancer VL - 46 UR - https://doi.org/10.1016/j.lungcan.2004.03.004 DO - 10.1016/j.lungcan.2004.03.004 ID - Zatloukal2004 ER - TY - JOUR AU - Huber, R. M. AU - FlentjeM, S. M. AU - PÖllinger, B. AU - Gosse, H. AU - Willner, J. PY - 2006 DA - 2006// TI - Simultaneouschemoradiotherapy compared with radiotherapy alone after induction chemotherapy in inoperable stage IIIA or IIIB non small-cell lung cancer: study CTRT99/97by the bronchial carcinoma therapy group JO - J Clin Oncol VL - 24 UR - https://doi.org/10.1200/JCO.2005.05.4163 DO - 10.1200/JCO.2005.05.4163 ID - Huber2006 ER - TY - JOUR AU - Clamon, G. AU - Herndon, J. AU - Cooper, R. AU - Chang, A. Y. AU - Rosenman, J. AU - Green, M. R. PY - 1999 DA - 1999// TI - Radiosensitization with carboplatin for patients with unresectable stage III non-small-cell lung cancer: a phase III trial of the Cancer and leukemia group B and the eastern cooperative oncology group JO - J Clin Oncol VL - 17 UR - https://doi.org/10.1200/JCO.1999.17.1.4 DO - 10.1200/JCO.1999.17.1.4 ID - Clamon1999 ER - TY - JOUR AU - Belderbos, J. AU - Uitterhoeve, L. AU - Zandwijk, N. AU - Belderbos, H. AU - Rodrigus, P. AU - Vaart, P. PY - 2007 DA - 2007// TI - Randomised trial of sequential versus concurrent chemo-radiotherapy in patients with inoperable non-small cell lung cancer (EORTC 08972-22973) JO - Eur J Cancer VL - 43 UR - https://doi.org/10.1016/j.ejca.2006.09.005 DO - 10.1016/j.ejca.2006.09.005 ID - Belderbos2007 ER - TY - JOUR AU - Groen, H. J. AU - Leest, A. H. AU - Fokkema, E. AU - Timmer, P. R. AU - Nossent, G. D. AU - Smit, W. J. PY - 2004 DA - 2004// TI - Continuously infused carboplatin used as radiosensitizer in locally unresectable non-small-cell lung cancer: A multicenter phase III study JO - Ann Oncol VL - 15 UR - https://doi.org/10.1093/annonc/mdh100 DO - 10.1093/annonc/mdh100 ID - Groen2004 ER - TY - JOUR AU - Fournel, P. AU - Robinet, G. AU - Thomas, P. AU - Souquet, P. J. AU - Léna, H. AU - Vergnenégre, A. PY - 2005 DA - 2005// TI - Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-saint-Etienne d'Oncologie Thoracique-Groupe Francais de PneumoCancerologie NPC 95-01 study JO - J Clin Oncol VL - 23 UR - https://doi.org/10.1200/JCO.2005.03.070 DO - 10.1200/JCO.2005.03.070 ID - Fournel2005 ER - TY - JOUR AU - Gervais, R. AU - Ducolone, A. AU - Lechevalier, T. AU - Legroumellec, A. AU - Lemarie, E. AU - Quoix, E. PY - 2005 DA - 2005// TI - Conventional radiation (RT) with daily carboplatin (Cb) compared to RT alone after induction chemotherapy (ICT) [vinorelbine (Vr)-cisplatine (P)]: final results of a randomized phase III trial in stage III unresectable non small cell lung (NSCLC) cancer. Study CRG/BMS/NPC/96 of the French lung cancer study group FNCLCC and IFCT JO - J Clin Oncol VL - 23 UR - https://doi.org/10.1200/jco.2005.23.16_suppl.7016 DO - 10.1200/jco.2005.23.16_suppl.7016 ID - Gervais2005 ER - TY - JOUR AU - Ready, N. AU - Jänne, P. AU - Bogart, J. AU - DiPetrillo, T. AU - Garst, J. AU - Graziano, S. PY - 2006 DA - 2006// TI - Chemoradiotherapy (CRT) and geftinib (G) in stage III non-small cell lung cancer (NSCLC): a CALGB stratifed phase II trial JO - J Clin Oncol VL - 24 UR - https://doi.org/10.1200/jco.2006.24.18_suppl.7046 DO - 10.1200/jco.2006.24.18_suppl.7046 ID - Ready2006 ER - TY - JOUR AU - Antonia, S. J. AU - Villegas, A. AU - Daniel, D. AU - Vicente, D. AU - Murakami, S. AU - Hui, R. PY - 2018 DA - 2018// TI - Overall survival with Durvalumab after Chemoradiotherapy in stage III NSCLC JO - N Engl J Med VL - 379 UR - https://doi.org/10.1056/NEJMoa1809697 DO - 10.1056/NEJMoa1809697 ID - Antonia2018 ER - TY - JOUR AU - Lilenbaum, R. AU - Samuels, M. AU - Wang, X. AU - Kong, F. M. AU - Jamme, P. A. AU - Masters, G. PY - 2015 DA - 2015// TI - A phase II study of induction chemotherapy followed by thoracic radiotherapy and erlotinib in poor-risk stage III non-small-cell lung cancer: results of CALGB 30605 (Alliance)/RTOG 0972 (NRG)[J] JO - J Thorac Oncol VL - 10 UR - https://doi.org/10.1097/JTO.0000000000000347 DO - 10.1097/JTO.0000000000000347 ID - Lilenbaum2015 ER - TY - JOUR AU - Atagi, S. AU - Kawahara, M. AU - Yokoyama, A. AU - Okamoto, H. AU - Yamamoto, N. AU - Ohe, Y. PY - 2012 DA - 2012// TI - Thoracic radiotherapy with or without daily low-dose carboplatin in elderly patients with non-small cell lung cancer: a randomized controlled, phase 3 trial by the Japan clinical oncology group (JCOG 0301) JO - Lancet Oncol VL - 13 UR - https://doi.org/10.1016/S1470-2045(12)70139-0 DO - 10.1016/S1470-2045(12)70139-0 ID - Atagi2012 ER - TY - JOUR AU - Martínez, E. AU - Martínez, M. AU - Rico, M. AU - Hemández, B. AU - Casas, F. AU - Viñolas, N. PY - 2016 DA - 2016// TI - Feasibility, tolerability, and effcacy of the concurrent addition of erlotinib to thoracic radiotherapy in locally advanced unresectable non-small cell lung cancer: a phase II trial JO - Oncol Targets Ther VL - 9 UR - https://doi.org/10.2147/OTT.S89755 DO - 10.2147/OTT.S89755 ID - Martínez2016 ER - TY - JOUR AU - Wang, J. AU - Xia, T. Y. AU - Wang, Y. J. AU - Li, H. Q. AU - Li, P. AU - Wang, J. D. PY - 2011 DA - 2011// TI - Prospective study of epidermal growth factor receptor tyrosine kinase inhibitors concurrent with individualized radiotherapy for patients with locally advanced or metastatic non-small cell lung cancer JO - Int J Radiat Oncol VL - 81 UR - https://doi.org/10.1016/j.ijrobp.2010.12.035 DO - 10.1016/j.ijrobp.2010.12.035 ID - Wang2011 ER - TY - JOUR AU - Zheng, L. P. AU - Wang, Y. AU - Xu, Z. AU - Yang, Q. AU - Zhu, G. AU - Liao, X. Y. PY - 2019 DA - 2019// TI - Concurrent EGFR-TKI and thoracic radiotherapy as first line treatment for stage IV non-small-cell lung cancer harboring EGFR active mutations JO - Oncologist VL - 24 UR - https://doi.org/10.1634/theoncologist.2019-0285 DO - 10.1634/theoncologist.2019-0285 ID - Zheng2019 ER - TY - JOUR AU - Ciardiello, F. AU - Tortora, G. PY - 2008 DA - 2008// TI - EGFR antagonists in cancer treatment JO - N Engl J Med VL - 358 UR - https://doi.org/10.1056/NEJMra0707704 DO - 10.1056/NEJMra0707704 ID - Ciardiello2008 ER - TY - JOUR AU - Dacic, S. AU - Flanagan, M. AU - Cieply, K. AU - Ramalingam, S. AU - Luketich, J. AU - Belani, C. PY - 2006 DA - 2006// TI - Significance of EGFR protein expression and gene amplification in non-small cell lung carcinoma JO - Am J Clin Pathol VL - 125 UR - https://doi.org/10.1309/H5UW6CPCWWC92241 DO - 10.1309/H5UW6CPCWWC92241 ID - Dacic2006 ER - TY - JOUR AU - Meert, A. P. AU - Martin, B. AU - Delmotte, P. AU - Berghmans, T. AU - Lafitte, J. J. AU - Mascaux, C. PY - 2002 DA - 2002// TI - The role of EGFR expression on patient survival in lung cancer: a review with meta-analysis JO - Eur Respir J VL - 9 ID - Meert2002 ER - TY - JOUR AU - Zhuang, H. AU - Yuan, Z. PY - 2014 DA - 2014// TI - Radiation pneumonitis in patients with non-small cell lung cancer treated with erlotinib concurrent with thoracic radiotherapy JO - J Thorac Oncol VL - 9 UR - https://doi.org/10.1097/JTO.0000000000000126 DO - 10.1097/JTO.0000000000000126 ID - Zhuang2014 ER - TY - JOUR AU - Ren, S. AU - Li, Y. AU - Li, W. AU - Zhao, Z. AU - Jin, C. AU - Zhang, D. PY - 2012 DA - 2012// TI - Fatal asymmetric interstitial lung disease after erlotinib for lung cancer JO - Respiration VL - 84 UR - https://doi.org/10.1159/000339508 DO - 10.1159/000339508 ID - Ren2012 ER - TY - JOUR AU - Tsubata, Y. AU - Hamada, A. AU - Sutani, A. AU - Isobe, T. PY - 2012 DA - 2012// TI - Erlotinib-induced acute interstitial lung disease associated with extreme elevation of the plasma concentration in an elderly non-small-cell lung cancer patient JO - J Cancer Res Ther VL - 8 UR - https://doi.org/10.4103/0973-1482.95201 DO - 10.4103/0973-1482.95201 ID - Tsubata2012 ER - TY - JOUR AU - Nanda, A. AU - Dias-Santagata, D. C. AU - Stubbs, H. AU - O’Hara, C. J. AU - Zaner, K. S. AU - Lynch, T. J. PY - 2008 DA - 2008// TI - Unusual tumor response and toxicity from radiation and concurrent erlotinib for non-small-cell lung cancer JO - Clin Lung Cancer VL - 9 UR - https://doi.org/10.3816/CLC.2008.n.044 DO - 10.3816/CLC.2008.n.044 ID - Nanda2008 ER - TY - JOUR AU - Chang, C. C. AU - Chi, K. H. AU - Kao, S. J. AU - Hsu, P. S. AU - Tsang, Y. W. AU - Chang, H. J. PY - 2011 DA - 2011// TI - Upfront geftinib/erlotinib treatment followed by concomitant radiotherapy for advanced lung cancer: a mono-institutional experience JO - Lung Cancer VL - 73 UR - https://doi.org/10.1016/j.lungcan.2010.12.007 DO - 10.1016/j.lungcan.2010.12.007 ID - Chang2011 ER -